About Microtubule-actin cross-linking factor 1, isoforms 1/2/3/4/5
Microtubule-actin cross-linking factor 1, isoforms 1/2/3/4/5 (MACF1) is a protein
from Homo sapiens identified by UniProt accession
Q9UPN3, 7388 residues long.
MolForge cross-references it against 0 known binders and
194 disease associations.
Target properties
| Protein name | Microtubule-actin cross-linking factor 1, isoforms 1/2/3/4/5 |
|---|
| UniProt accession | Q9UPN3 |
|---|
| Gene | MACF1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 7388 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (194)
Diseases linked to this target (Open Targets).
- lissencephaly 9 with complex brainstem malformation · score 0.77
- Lissencephaly · score 0.57
- Intellectual disability · score 0.50
- Seizure · score 0.49
- Brainstem dysplasia · score 0.46
- body mass index · score 0.37
- high density lipoprotein cholesterol measurement · score 0.37
- Short stature · score 0.35
- lean body mass · score 0.34
- sex hormone-binding globulin measurement · score 0.33
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (7388 residues)
MSSSDEETLS ERSCRSERSC RSERSYRSER SGSLSPCPPG DTLPWNLPLH EQKKRKSQDS VLDPAERAVV RVADERDRVQ KKTFTKWVNK HLMKVRKHIN DLYEDLRDGH NLISLLEVLS GIKLPREKGR MRFHRLQNVQ IALDFLKQRQ VKLVNIRNDD ITDGNPKLTL GLIWTIILHF QISDIYISGE SGDMSAKEKL LLWTQKVTAG YTGIKCTNFS SCWSDGKMFN ALIHRYRPDL VDMERVQIQS NRENLEQAFE VAERLGVTRL LDAEDVDVPS PDEKSVITYV SSIYDAFPKV PEGGEGISAT EVDSRWQEYQ SRVDSLIPWI KQHTILMSDK TFPQNPVELK ALYNQYIHFK ETEILAKERE KGRIEELYKL LEVWIEFGRI KLPQGYHPND VEEEWGKLII EMLEREKSLR PAVERLELLL QIANKIQNGA LNCEEKLTLA KNTLQADAAH LESGQPVQCE SDVIMYIQEC EGLIRQLQVD LQILRDENYY QLEELAFRVM RLQDELVTLR LECTNLYRKG HFTSLELVPP STLTTTHLKA EPLTKATHSS STSWFRKPMT RAELVAISSS EDEGNLRFVY ELLSWVEEMQ MKLERAEWGN DLPSVELQLE TQQHIHTSVE ELGSSVKEAR LYEGKMSQNF HTSYAETLGK LETQYCKLKE TSSFRMRHLQ SLHKFVSRAT AELIWLNEKE EEELAYDWSD NNSNISAKRN YFSELTMELE EKQDVFRSLQ DTAELLSLEN HPAKQTVEAY SAAVQSQLQW MKQLCLCVEQ HVKENTAYFQ FFSDARELES FLRNLQDSIK RKYSCDHNTS LSRLEDLLQD SMDEKEQLIQ SKSSVASLVG RSKTIVQLKP RSPDHVLKNT ISVKAVCDYR QIEITICKND ECVLEDNSQR TKWKVISPTG NEAMVPSVCF LIPPPNKDAI EMASRVEQSY QKVMALWHQL HVNTKSLISW NYLRKDLDLV QTWNLEKLRS SAPGECHQIM KNLQAHYEDF LQDSRDSVLF SVADRLRLEE EVEACKARFQ HLMKSMENED KEETVAKMYI SELKNIRLRL EEYEQRVVKR IQSLASSRTD RDAWQDNALR IAEQEHTQED LQQLRSDLDA VSMKCDSFLH QSPSSSSVPT LRSELNLLVE KMDHVYGLST VYLNKLKTVD VIVRSIQDAE LLVKGYEIKL SQEEVVLADL SALEAHWSTL RHWLSDVKDK NSVFSVLDEE IAKAKVVAEQ MSRLTPERNL DLERYQEKGS QLQERWHRVI AQLEIRQSEL ESIQEVLGDY RACHGTLIKW IEETTAQQEM MKPGQAEDSR VLSEQLSQQT ALFAEIERNQ TKLDQCQKFS QQYSTIVKDY ELQLMTYKAF VESQQKSPGK RRRMLSSSDA ITQEFMDLRT RYTALVTLTT QHVKYISDAL RRLEEEEKVV EEEKQEHVEK VKELLGWVST LARNTQGKAT SSETKESTDI EKAILEQQVL SEELTTKKEQ VSEAIKTSQI FLAKHGHKLS EKEKKQISEQ LNALNKAYHD LCDGSANQLQ QLQSQLAHQT EQKECRAVAG VIDLGTVEIF PIFKAMQKGL LDQDTGLVLL ESQVIMSGLI APETGENLSL EEGIARNLIN PQMYQQLREL QDALALISRL TESRGPLSVV EAIEKRIISE TVGLKILEAH LATGGFSLSP SENCINLEEA FHQGLISAWL HSVLESYLRT SKNLIDPNTA EKIGLLDLMQ RCIVHQESGF KLLPVKQLAG GMVSLKSGRK VSIFRAVQEG LIDRQVTVRL LEAQLFAGGI VDPRTGHRLT VEEAVRHNLI DQDMACAILI RQLQTGGIID TVTGQRLTID EAVSNDLVAA KIALVILESL WSFMGLLWPE SGEILPITDA LEQGIVSTEL AHKILSNRQH IKALFLPATT EILSWKKAIE SGILDRDLAN NLKSICIPDV MPHMQLADSA EQNINPGAAV LPCSKSHPKA TASQSENLLF QLMTHSYINV QNGQRLLLLD KELMETLTSR DEYQTSPPKV VEIGHQRQKT PEGLQESANV KISGTFSSGW TVRLPEFQFS SQNKEYPDRE DCTTEKGKKT TVETEDSSVE NPEQDLFVEQ KERNPNIDAL KVINKVKLEV QRQLIGTQRE DQTAVSVREN ASRGHLLTIP PAEAEGVPLV VDKDVFSVET PKKEHQPLRN TSFTCQNEQA HTLETEYIHD ETGGSHIKPQ SKKLQVQVKK TLGIKLELKS ETDGNVHPLD KKEMLKKTFL AKDDHKESQE AQNIAGGSMM MSEKTDEEDS GREIFLSCSH PLELLEEATL NVLSAQLLDG GIFHEQTGQK LLLNEAISRG IVPSHTAVKL MEKLNMFQGF FDSQTCESLT TEEVINEGLM DEKLLHNVLM ADKAISGVLD PRTQTLCSVK DAVTVGLLDK ETATRILERQ VVTGGIIDLK RGKKVSVTLA STLGLVDVAD QPELINLEKA SKGRDAEKTV RERLISLQME TTGLIDPDSK APLTVVQSID RGLLEREEAV RLLTKQVVDG GIIHHISGMR LSVDNAFRHG LIGEDLAEKL KRVENLNIHQ IFNPETKENI SLPKAIKLDL ITSDLKREIQ EVQAFTGNFV DLISGQRLTL AEAKKEGLLT NEAVLSPGMM HGIVDPENCR IVPYSELVKK CKIDIESGQR YLEVIPFSDI KDGVSDKVLT LSQAIQLGKV DFASTLKVLE AQANTGGIID TATGKRLTLA SALEEKLVDE NMVRIIASHQ VLNGGIVDIF SDQRVTLVEA IEKRLISPEL ANMIQIDSSE FSDHRAQIEK QEGIEVCALQ NEFLGKDMLI ACNQTAEMSC NKVEESERLF QVENQSAQEK VKVRVSDGEQ AKKSREISLK EFGCKDQRKP RMSSDAKEFI SIINPHNLKG KSLGQVSLTH PYSECDFKLK EVARNNMGND TNEEQEKAVT KIEIISHMKQ STSCLDSEEI RENQGEVILE VQETYCETSG KLPSEQVLQQ PMNARVKSKR EKREVIVEES IRTCKPAFLS EEKLYQETAI RDEHDSHIKS QPREMTSSEK GKEADTEMGF SITFKIEESS SQVVPQGISV KHLDALTLFS SKQANEGKVN NLSLCLTLKP EENLSREIAC GAQSEPFPCM TPRPEGLHYQ ESDGKAQVTG PSQISKTDKS FQGTTRQETN YQDSWVTSKT KETKHQISSS NECKEKSYQE VSFDPARGLK LEEITVSRPD SKEVRYLEFS DRKDLHHQGS KSDDKLCGTL KSEIATQELT GEKFLEMANP NVAGLEAGSI EDIVTQRGSR VLGSFLPEKL FKGVSQKENT GQQNAIISPT VLETSEEKTV SLTVCSAVKT EKTPQEKLRE SPGSEQTPFM TAPEGKGNGG VNPEPFRATQ NVFTRQLCLE HDEKLVSYLS LLRNIEMRTK QIQPLELNLA ELQDLLCQAK VLERELKDLT TLVSQELECV NQIIISQPQE VPAQLLKALE KDAKNLQKSL SSVSDTWNSR LLHFQNAVEI EKTKVLNQHT QLEGRLQDLR AWVGNKNLIL NSKGSNSEID VDSLNLCLQQ YEDLKQPMAE RKAQLDALAF DIQFFISEHA QDLSPQQNRQ MLRLLNELQR SFQDILEQTA AQVDALQGHL QQMEQEALVK TLQKQQNTCH QQLEDLCSWV GQAERALAGH QGRTTQQDLS ALQKNQSDLK DLQDDIQNRA TSFATVVKDI EGFMEENQTK LSPRELTALR EKLHQAKEQY EALQEETRVA QKELEEAVTS ALQQETEKSK AAKELAENKK KIDALLDWVT SVGSSGGQLL TNLPGMEQLS GASLEKGALD TTDGYMGVNQ APEKLDKQCE MMKARHQELL SQQQNFILAT QSAQAFLDQH GHNLTPEEQQ MLQQKLGELK EQYSTSLAQS EAELKQVQTL QDELQKFLQD HKEFESWLER SEKELENMHK GGSSPETLPS LLKRQGSFSE DVISHKGDLR FVTISGQKVL DMENSFKEGK EPSEIGNLVK DKLKDATERY TALHSKCTRL GSHLNMLLGQ YHQFQNSADS LQAWMQACEA NVEKLLSDTV ASDPGVLQEQ LATTKQLQEE LAEHQVPVEK LQKVARDIME IEGEPAPDHR HVQETTDSIL SHFQSLSYSL AERSSLLQKA IAQSQSVQES LESLLQSIGE VEQNLEGKQV SSLSSGVIQE ALATNMKLKQ DIARQKSSLE ATREMVTRFM ETADSTTAAV LQGKLAEVSQ RFEQLCLQQQ EKESSLKKLL PQAEMFEHLS GKLQQFMENK SRMLASGNQP DQDITHFFQQ IQELNLEMED QQENLDTLEH LVTELSSCGF ALDLCQHQDR VQNLRKDFTE LQKTVKEREK DASSCQEQLD EFRKLVRTFQ KWLKETEGSI PPTETSMSAK ELEKQIEHLK SLLDDWASKG TLVEEINCKG TSLENLIMEI TAPDSQGKTG SILPSVGSSV GSVNGYHTCK DLTEIQCDMS DVNLKYEKLG GVLHERQESL QAILNRMEEV HKEANSVLQW LESKEEVLKS MDAMSSPTKT ETVKAQAESN KAFLAELEQN SPKIQKVKEA LAGLLVTYPN SQEAENWKKI QEELNSRWER ATEVTVARQR QLEESASHLA CFQAAESQLR PWLMEKELMM GVLGPLSIDP NMLNAQKQQV QFMLKEFEAR RQQHEQLNEA AQGILTGPGD VSLSTSQVQK ELQSINQKWV ELTDKLNSRS SQIDQAIVKS TQYQELLQDL SEKVRAVGQR LSVQSAISTQ PEAVKQQLEE TSEIRSDLEQ LDHEVKEAQT LCDELSVLIG EQYLKDELKK RLETVALPLQ GLEDLAADRI NRLQAALAST QQFQQMFDEL RTWLDDKQSQ QAKNCPISAK LERLQSQLQE NEEFQKSLNQ HSGSYEVIVA EGESLLLSVP PGEEKRTLQN QLVELKNHWE ELSKKTADRQ SRLKDCMQKA QKYQWHVEDL VPWIEDCKAK MSELRVTLDP VQLESSLLRS KAMLNEVEKR RSLLEILNSA ADILINSSEA DEDGIRDEKA GINQNMDAVT EELQAKTGSL EEMTQRLREF QESFKNIEKK VEGAKHQLEI FDALGSQACS NKNLEKLRAQ QEVLQALEPQ VDYLRNFTQG LVEDAPDGSD ASQLLHQAEV AQQEFLEVKQ RVNSGCVMME NKLEGIGQFH CRVREMFSQL ADLDDELDGM GAIGRDTDSL QSQIEDVRLF LNKIHVLKLD IEASEAECRH MLEEEGTLDL LGLKRELEAL NKQCGKLTER GKARQEQLEL TLGRVEDFYR KLKGLNDATT AAEEAEALQW VVGTEVEIIN QQLADFKMFQ KEQVDPLQMK LQQVNGLGQG LIQSAGKDCD VQGLEHDMEE INARWNTLNK KVAQRIAQLQ EALLHCGKFQ DALEPLLSWL ADTEELIANQ KPPSAEYKVV KAQIQEQKLL QRLLDDRKAT VDMLQAEGGR IAQSAELADR EKITGQLESL ESRWTELLSK AAARQKQLED ILVLAKQFHE TAEPISDFLS VTEKKLANSE PVGTQTAKIQ QQIIRHKALN EEIVNRKKNV DQAIKNGQAL LKQTTGEEVL LIQEKLDGIK TRYADITVTS SKALRTLEQA RQLATKFQST YEELTGWLRE VEEELATSGG QSPTGEQIPQ FQQRQKELKK EVMEHRLVLD TVNEVSRALL ELVPWRAREG LDKLVSDANE QYKLVSDTIG QRVDEIDAAI QRSQQYEQAA DAELAWVAET KRKLMALGPI RLEQDQTTAQ LQVQKAFSID IIRHKDSMDE LFSHRSEIFG TCGEEQKTVL QEKTESLIQQ YEAISLLNSE RYARLERAQV LVNQFWETYE ELSPWIEETR ALIAQLPSPA IDHEQLRQQQ EEMRQLRESI AEHKPHIDKL LKIGPQLKEL NPEEGEMVEE KYQKAENMYA QIKEEVRQRA LALDEAVSQS TQITEFHDKI EPMLETLENL SSRLRMPPLI PAEVDKIREC ISDNKSATVE LEKLQPSFEA LKRRGEELIG RSQGADKDLA AKEIQDKLDQ MVFFWEDIKA RAEEREIKFL
Explore Microtubule-actin cross-linking factor 1, isoforms 1/2/3/4/5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets